York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high-quality and effective rapid tests, notes that a judgement in relation to the
Abingdon Health PLC (AIM:ABDX) Supply agreement for Abingdon COVID-19 tests
Purchase of 10m Abingdon Health Simply Test COVID-19 antigen tests; subject to Taiwan FDA approval of test
Abingdon Health PLC (AIM:ABDX) DeepVerge Testing Services Framework Agreement
York, U.K. 30 May 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that it has signed a Testing
Abingdon Health PLC (AIM:ABDX) Significant contract to manufacture LFD components
Significant contract signed to manufacture lateral flow device components
Abingdon Health PLC (AIM:ABDX) Strategic collaboration with Bimelix Ab
Focused on the on development and commercialisation of Lyme disease lateral flow self-test
Abingdon Health PLC (AIM:ABDX) Completion of Technical Transfer & initial orders
Completion of Technical Transfer to full-scale manufacture and initial orders for Vatic KnowNowTM test
Abingdon Health PLC (ABDX.L) Update on AffiDX® SARS-CoV-2 antigen LFT
Technical transfer completed mid-December as planned
Abingdon Health PLC (ABDX.L) Preliminary Results
York, U.K. 18 November 2021: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces its preliminary results for the year
Abingdon Health PLC (ABDX.L) Launch of Semi-Quantitative Accessory to AbC-19T
To help indicate the strength of antibody response and possible immunity
Abingdon Health PLC (ABDX.L) Launch of BioSURE COVID-19 IgG Antibody Self Test
Contract manufacturing for CE marked self-test to monitor antibody status
Abingdon Health PLC (ABDX.L) Exclusive Manufacturing Agreement with BioSure
Exclusive Lateral Flow Manufacturing Agreement with BioSure UK Limited